SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?


To: Biomaven who wrote (6909)5/27/2003 5:55:19 PM
From: Icebrg  Read Replies (1) | Respond to of 10280
 
>>There is a potential FTC glitch with Soltara. Of course they could just abandon it, or try to offload it.>>

They could abandon Claritin, let Clarinex go OTC (as it is anyhow more or less the same thing and FDA will not put up much of a resistance) and finally keep Soltara as their prescription drug. I am sure they would like that set-up. They could claim more efficacy both with and without a prescription.

Erik